We conjecture that the low rate of mortality and development of cryptococcal meningitis observed among screen positive individuals in this cohort as compared to prior studies with ART-naïve individuals is related to high rates of successful ART receipt at baseline (26 of 31 of CRAG positive individuals), higher CD4 counts at baseline (18 of 31 had CD4>100 cells/μl), and a survivorship bias resulting from a long duration of previous therapy (37 months) [4]. The gene discussed is CD4; the disease is Cryptococcal meningitis.